PMID- 26207146
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 1758-4299 (Print)
IS  - 1758-4302 (Electronic)
IS  - 1758-4302 (Linking)
VI  - 6
IP  - 1
DP  - 2011
TI  - The ACCORD-Lipid study: implications for treatment of dyslipidemia in Type 2 
      diabetes mellitus.
PG  - 9-20
AB  - Patients with Type 2 diabetes mellitus (T2DM) are at high risk of developing 
      cardiovascular disease (CVD). Treatment of diabetic dyslipidemia, comprised 
      mainly of hypertriglyceridemia, and low HDL-C, with either statin or fibrate 
      monotherapy, is moderately effective at reversing the abnormal lipid levels, but 
      does not completely reverse the risk of CVD. Combination therapy with a statin 
      and fibrate more effectively treats diabetic dyslipidemia; however, neither the 
      impact on CVD risk nor the safety profile of statin-fibrate combined treatment 
      had been tested in a large randomized trial. The Action to Control Cardiovascular 
      Risk in Diabetes (ACCORD)-Lipid trial tested the hypothesis that combination 
      therapy with a fibrate and statin would more effectively prevent major CVD events 
      in a high-risk population of patients with T2DM compared with statin monotherapy. 
      In ACCORD-Lipid, over 5000 patients were treated with fenofibrate plus 
      simvastatin versus simvastatin alone. Although combination therapy did not 
      significantly reduce CVD event rates in the ACCORD-Lipid cohort as a whole, a 
      predefined subgroup of participants with the combination of significant 
      hypertriglyceridemia and low HDL-C experienced a 31% lower event rate with 
      combination therapy. Post hoc analyses conducted in similar subsets in previous 
      fibrate monotherapy trials were concordant with these findings in ACCORD-Lipid. 
      Combination therapy was well tolerated and safe, with no detectable increase in 
      myopathy. The implications of the ACCORD-Lipid findings for the treatment of 
      dyslipidemia in patients with T2DM are discussed.
FAU - Elam, Marshall
AU  - Elam M
AD  - Section of Epidemiology, Department of Public Health Sciences, Wake Forest 
      University - School of Medicine, Medical Center Boulevard, Winston Salem, NC 
      27157-1063, USA.
FAU - Lovato, Laura
AU  - Lovato L
AD  - Section of Epidemiology, Department of Public Health Sciences, Wake Forest 
      University - School of Medicine, Medical Center Boulevard, Winston Salem, NC 
      27157-1063, USA.
FAU - Ginsberg, Henry
AU  - Ginsberg H
AD  - Department of Medicine, College of Physicians & Surgeons of Columbia University, 
      PH-10-305, 630 West 168th Street, New York, NY 10032, USA.
LA  - eng
GR  - N01 HC095178/HC/NHLBI NIH HHS/United States
GR  - Y01 HC001010/HC/NHLBI NIH HHS/United States
GR  - Y01 HC009035/HC/NHLBI NIH HHS/United States
GR  - N01 HC095184/HC/NHLBI NIH HHS/United States
GR  - N01 HC095180/HC/NHLBI NIH HHS/United States
GR  - N01 HC095183/HC/NHLBI NIH HHS/United States
GR  - N01 HC095179/HC/NHLBI NIH HHS/United States
GR  - N01 HC095181/HC/NHLBI NIH HHS/United States
GR  - N01 HC095182/HC/NHLBI NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Clin Lipidol
JT  - Clinical lipidology
JID - 101502551
PMC - PMC4509601
MID - NIHMS296246
OTO - NOTNLM
OT  - HDL-C
OT  - coronary heart disease
OT  - diabetes
OT  - dyslipidemia
OT  - fenofibrate
OT  - simvastatin
OT  - stroke
OT  - triglyceride
EDAT- 2011/01/01 00:00
MHDA- 2011/01/01 00:01
PMCR- 2015/07/21
CRDT- 2015/07/25 06:00
PHST- 2015/07/25 06:00 [entrez]
PHST- 2011/01/01 00:00 [pubmed]
PHST- 2011/01/01 00:01 [medline]
PHST- 2015/07/21 00:00 [pmc-release]
AID - 10.2217/clp.10.84 [doi]
PST - ppublish
SO  - Clin Lipidol. 2011;6(1):9-20. doi: 10.2217/clp.10.84.